Join PDS Biotechnology for a virtual key opinion leader (KOL) event featuring Kevin Harrington, MBBS, PhD (The Institute of Cancer Research, United Kingdom) and Katharine A. Price, MD (Head and Neck Disease Group, Mayo Clinic Comprehensive Cancer Center), who will discuss the unmet need and current treatment landscape for recurrent/metastatic HPV16-positive HNSCC (head and neck squamous cell carcinoma).

The event will review the changing landscape of HNSCC with respect to Merck’s KN-689 study and the rapidly increasing incidences of HPV16-positive HNSCC in the US and Europe. The event will review Versamune^® HPV, which is currently being evaluated in a Phase 3 clinical trial in combination with pembrolizumab as a first-line treatment for R/M HPV16+ HNSCC, as well as in Phase 2 clinical trials for the treatment of various types of HPV16-positive cancers. Versamune^® HPV is a novel investigational human papilloma virus (HPV)-targeted immunotherapy that stimulates a potent targeted T cell attack against HPV-positive cancers. The panel will discuss the emerging treatment landscape in 1L r/m HNSCC, the view of HPV-positive and HPV-negative HNSCC as two distinct diseases with different underlying causes, pathology, and contributions to the development of HNSCC, as well as identification and treatment of HPV16+ HNSCC.

A live question and answer session will follow the formal presentations.